Understanding how the immune system responds to Clostridioides difficile infection
Project 3: Defining adaptive immune interactions that shape Clostridioides difficile infection
['FUNDING_OTHER'] · UNIVERSITY OF PENNSYLVANIA · NIH-11037959
This study is looking at why some people who recover from a Clostridioides difficile infection don’t seem to build lasting immunity, and it aims to find ways to help protect those at higher risk from getting sick again.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11037959 on ClinicalTrials.gov |
What this research studies
This research investigates the immune response to Clostridioides difficile infection, focusing on why some patients do not develop lasting immunity after recovering from the infection. By analyzing patient samples and using a mouse model, the study aims to identify the immune parameters that contribute to effective immunity. The researchers will compare the ability of antibodies produced during infection to recognize and bind to the bacteria in the intestines, which is crucial for developing effective vaccines. The goal is to uncover mechanisms that could lead to better prevention strategies for high-risk populations.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have experienced Clostridioides difficile infections, particularly those who have had recurrent episodes.
Not a fit: Patients who have never been infected with Clostridioides difficile or those with unrelated gastrointestinal conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a vaccine that provides lasting protection against Clostridioides difficile infections.
How similar studies have performed: Previous research has shown that understanding immune responses can lead to successful vaccine development, but this specific approach to Clostridioides difficile is relatively novel.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ABT, MICHAEL C. — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: ABT, MICHAEL C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.